Cardiovascular effects of 2-arachidonoyl glycerol in anesthetized mice

Hypertension

Volumn 35, Issue 2, 2000, Pages 679-684

  Járai, Zoltán ^a   Wagner, Jens A ^a,e   Goparaju, Sravan Kumar ^a   Wang, Lei ^a   Razdan, Raj K ^b   Sugiura, Takayuki ^c   Zimmer, Ann M ^d   Bonner, Tom I ^d   Zimmer, Andreas ^d   Kunos, George ^a,f  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ORGANIX INC   (United States)

^c TEIKYO UNIVERSITY   (Japan)

^d NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^e UNIVERSITY OF WÜRZBURG   (Germany)

^f VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Cannabinoid; Hypotension; Mice; Receptors

Indexed keywords

2 ARACHIDONOYLGLYCEROL; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; ANANDAMIDE; ARACHIDONIC ACID; ARACHIDONIC ACID DERIVATIVE; CANNABINOID RECEPTOR; INDOMETACIN; RIMONABANT; TRIACYLGLYCEROL LIPASE;

ANESTHESIA; ANIMAL EXPERIMENT; ARTICLE; BRADYCARDIA; CARDIOVASCULAR EFFECT; CONTROLLED STUDY; DRUG DEGRADATION; DRUG EFFECT; FEMALE; HEART RATE; HYPOTENSION; MALE; MEAN ARTERIAL PRESSURE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0033952018     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.35.2.679     Document Type: Article

References (31)

1. 9-trans-tetrahydrocannabinol. J Pharm Pharmacol. 1974; 26:186-198.
2. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 1992;258:1946-1949.
3. 1 cannabinoid receptor in the hypotensive action of anandamide. Eur J Pharmacol. 1995;278:279-283.
4. Varga K, Lake KD, Huangfu D, Guyenet PG, Kunos G. Mechanism of the hypotensive action of anandamide in anesthetized rats. Hypertension. 1996;28:682-686.
5. 1-like cannabinoid receptors. J Pharmacol Exp Ther. 1997;281:1030-1037.
6. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 1990;346:561-564.
7. Rinaldi-Carmona M, Barth F, Heaulme M, Shire D, Calandra B, Congy C, Martinez S, Maruani J, Neliat G, Caput D, Ferrara P, Soubrie P, Breliere JC, Le Fur G. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. 1994;350:240-244.
8. Ledent C, Valverde O, Cossu G, Petitet F, Aubert J-F, Beslot F, Böhme GA, Imperato A, Pedrazzini T, Roques BP, Vassart G, Fratta W, Parmentier M. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 1999;283: 401-404.
9. Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR, Gopher A, Almog S, Martin BR, Compton DR, Pertwee RG, Griffin G, Bayewitch M, Barg J, Vogel Z. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol. 1995;50:83-90.
10. Sugiura T, Kondo S, Sukagawa A, Nakane S, Shinoda A, Itoh K, Yamashita A, Waku K. 2-Arachidonylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophvs Res Commun 1995;215:89-97.
11. Stella N, Schweitzer P, Piomelli D. A second endogenous cannabinoid that modulates long-term potentiation. Nature. 1997;388:773-778.
12. Mackie K, Devane WA, Hille B. Anandamide, an endogenous cannabinoid, inhibits calcium currents as a partial agonist in N18 neuroblastoma cells. Mol Pharmacol. 1993;44:498-503.
13. Fride E, Barg J, Levy R, Saya D, Heldman E, Mechoulam R, Vogel Z. Low doses of anandamides inhibit pharmacological effects of delta 9-tetrahydrocannabinol. J Pharmacol Exp Ther. 1995;272:699-707.
14. Burkey TH, Quock RM, Consroe P, Ehlert FJ, Hosohata Y, Roeske WR, Yamamura HI. Relative efficacies of cannabinoid CB1 receptor agonists in the mouse brain. Eur J Pharmacol. 1997;336:295-298.
15. 2+ channel current. Am J Physiol. 1999;276: H2085-H2093.
16. 2+ transient in NG108-15 cells. J Biochem. 1997;122:890-895.
17. Sugiura T, Kodaka T, Nakane S, Miyashita T, Kondo S, Suhara Y, Takayama H, Waku K, Seki C, Baba N, Ishima Y. Evidence that the cannabinoid CB1 receptor is a 2-arachidonoylglycerol receptor. J Biol Chem. 1999;274:2794-2801.
18. Randall MD, Alexander SPH, Bennett T, Boyd EA, Fry JR, Gardiner SM, Kemp PA, McCulloch AI, Kendall DA. An endogenous cannabinoid as an endothelium-derived vasorelaxant. Biochem Biophys Res Commun. 1996;229:114-120.
19. White R, Hiley CR. A comparison of EDHF-mediated and anandamide-induced relaxations in the rat isolated mesenteric artery. Br J Pharmacol. 1997;122:1573-1584.
20. Deutsch DG, Goligorsky MS, Schmid PC, Krebsbach RJ, Schmid HH, Das SK, Dey SK, Arreaza G, Thorup C, Stefano G, Moore LC. Production and physiological actions of anandamide in the vasculature of the rat kidney. J Clin Invest. 1997;100:1538-1546.
21. Wagner JA, Varga K, Ellis EF, Rzigalinski BA, Martin BR, Kunos G. Activation of peripheral CB1 cannabinoid receptors in haemorrhagic shock. Nature. 1997;390:518-521.
22. Varga K, Wagner JA, Bridgen TD, Kunos G. Platelet-and macrophage-derived endogenous cannabinoids are involved in endotoxin-induced hypotension. FASEB J. 1998;12:1035-1044.
23. Sugiura T, Kodaka T, Nakane S, Kishimoto S, Kondo S, Waku K. Detection of an endogenous cannabinoid molecule, 2-arachidonoylglycerol, and cannabinoid CB1 receptor mRNA in human vascular cells: is 2-arachidonoylglycerol a possible vasomodulator? Biochem Biophys Res Commun. 1998;243:838-843.
24. Mechoulam R, Fride E, Ben-Shabat S, Mein U, Horowitz M. Carbachol, an acetylcholine receptor agonist, enhances production in rat aorta of 2-arachidonoyl glycerol, a hypotensive endocannabinoid. Eur J Pharmacol. 1998;362:R1-R3.
25. Zimmer A, Zimmer AM, Hohmann AG, Herkenham M, Bonner TI. Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc Natl Acad Sci USA. 1999;96:5780-5785.
26. Han L, Razdan RK. Total synthesis of 2-arachidonoylglycerol. Tetrahedron Lett. 1999;40:1631-1634.
27. Rinaldi-Carmona M, Earth F, Millan J, Derocq J-M, Casellas P, Conay C, Oustric D, Sarran M, Bouaboula M, Calandra B, Portier M, Shire D, Breliere J-C, Le Fur G. SR144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J Pharmacol Exp Ther. 1998;284: 644-650.
28. Goparaju SK, Ueda N, Yamaguchi H, Yamamoto S. Anandamide amidohydrolase reacting with 2-arachidonoylglycerol, another cannabinoid receptor ligand. FEBS Lett. 1998;422:69-73.
29. Goparaju SK, Ueda N, Taniguchi K, Yamamoto S. Enzymes of porcine brain hydrolyzing 2-arachidonoylglycerol, an endogenous ligand of cannabinoid receptors. Biochem Pharmacol. 1999;57:417-423.
30. Di Marzo V, Bisogno T, De Petrocellis L, Melck D, Orlando P, Wagner JA, Kunos G. Biosynthesis and inactivation of endocannabinoid 2-arachidonylglycerol in circulating and tumoral macrophages. Eur J Biochem. 1999;264:258-267.
31. Ben-Shabat S, Fride E, Sheskin T, Tamiri T, Rhee MH, Vogel Z, Bisogno T, De Petrocellis L, Di Marzo V, Mechoulam R. An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. Eur J Pharmacol. 1998;353:23-31.